COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
Brian P. Epling, Joseph M. Rocco, Kristin L. Boswell, Elizabeth Laidlaw, Frances Galindo, Anela Kellogg, Sanchita Das, Allison Roder, Elodie Ghedin, Allie Kreitman, Robin L. Dewar, Sophie E. M. Kelly, Heather Kalish, Tauseef Rehman, Jeroen Highbarger, Adam Rupert, Gregory Kocher, Michael R. Holbrook, Andrea Lisco, Maura Manion, Richard A. Koup, Irini Sereti
doi: https://doi.org/10.1101/2022.06.16.22276392
Brian P. Epling
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Joseph M. Rocco
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Kristin L. Boswell
2Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Elizabeth Laidlaw
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Frances Galindo
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Anela Kellogg
3Clinical Research Directorate (CRD), Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA
Sanchita Das
4Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
Allison Roder
5Systems Genomics Section, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Elodie Ghedin
5Systems Genomics Section, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Allie Kreitman
5Systems Genomics Section, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Robin L. Dewar
6Virus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, MD, USA
Sophie E. M. Kelly
7Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA
Heather Kalish
7Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA
Tauseef Rehman
6Virus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, MD, USA
Jeroen Highbarger
6Virus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, MD, USA
Adam Rupert
8AIDS Monitoring Laboratory, Frederick National Laboratory, Frederick, MD, USA
Gregory Kocher
9Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA
Michael R. Holbrook
9Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA
Andrea Lisco
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Maura Manion
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Richard A. Koup
2Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Irini Sereti
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Article usage
Posted June 17, 2022.
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
Brian P. Epling, Joseph M. Rocco, Kristin L. Boswell, Elizabeth Laidlaw, Frances Galindo, Anela Kellogg, Sanchita Das, Allison Roder, Elodie Ghedin, Allie Kreitman, Robin L. Dewar, Sophie E. M. Kelly, Heather Kalish, Tauseef Rehman, Jeroen Highbarger, Adam Rupert, Gregory Kocher, Michael R. Holbrook, Andrea Lisco, Maura Manion, Richard A. Koup, Irini Sereti
medRxiv 2022.06.16.22276392; doi: https://doi.org/10.1101/2022.06.16.22276392
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
Brian P. Epling, Joseph M. Rocco, Kristin L. Boswell, Elizabeth Laidlaw, Frances Galindo, Anela Kellogg, Sanchita Das, Allison Roder, Elodie Ghedin, Allie Kreitman, Robin L. Dewar, Sophie E. M. Kelly, Heather Kalish, Tauseef Rehman, Jeroen Highbarger, Adam Rupert, Gregory Kocher, Michael R. Holbrook, Andrea Lisco, Maura Manion, Richard A. Koup, Irini Sereti
medRxiv 2022.06.16.22276392; doi: https://doi.org/10.1101/2022.06.16.22276392
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2256)
- Dermatology (201)
- Emergency Medicine (368)
- Epidemiology (11547)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3541)
- Geriatric Medicine (336)
- Health Economics (611)
- Health Informatics (2286)
- Health Policy (910)
- Hematology (333)
- HIV/AIDS (742)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3324)
- Nursing (190)
- Nutrition (504)
- Oncology (1747)
- Ophthalmology (522)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (222)
- Palliative Medicine (66)
- Pathology (435)
- Pediatrics (998)
- Primary Care Research (399)
- Public and Global Health (5971)
- Radiology and Imaging (1216)
- Respiratory Medicine (807)
- Rheumatology (367)
- Sports Medicine (311)
- Surgery (383)
- Toxicology (50)
- Transplantation (170)
- Urology (142)